Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-520-3
CAS number: 10213-78-2
Exposure to the substance is very unlikely by inhalation due to the extremely low vapour pressure and its physical form of a waxy solid. Ingestion is not a likely route of exposure and the irritant effects would limit accidental oral exposure. The irritant properties of the substance will limit the potential for repeated or prolonged skin exposure so dermal absorption should be limited. There is data available on the metabolism of the related primary amines which is considered appropriate also for the .2,2’-(Octadecylimino)bisethanol) CAS No 10213-78-2.
Exposure to 2,2’-(Octadecylimino)bisethanol)
CAS No 10213-78-2 is very unlikely by inhalation due to the extremely
low vapour pressure and its physical form which is a waxy solid at
ambient temperatures. Ingestion is not a likely route of exposure and
the corrosive / irritant effects would limit accidental oral exposure.
The irritant properties of the substance will limit the potential for
repeated or prolonged skin exposure so dermal absorption should be
limited. It is likely that once this substance enters the body due to
its lipophilic nature that it would be transported via the lymphatic
system to the nearest draining lymph node rather than in the blood. This
is supported by evidence from oral dosing studies in animals which
indicate that in digestive tract similar test substances (e.g.
2,2’-(C16-18 (even numbered, C18 unsaturated) alkyl imino) diethanol CAS
No 1218787-32-6) when absorbed are transported to the draining
mesenteric lymph nodes. It is likely that the
macrophages will then ingest the material and it would then be
Due to the irritant nature of this substance
the required risk management measures to handle them should minimise the
potential for contact with the skin. The initial strong irritant effects
might be expected to compromise the barrier properties of the skin to
some extent, exposure to the test substance would have to be assumed to
result in 100% absorption. For formulation containing the test substance
the high octanol water partition coefficient of Log Kow 3.8 would reduce
its potential for being absorbed through the skin. Although the test
substance molecular weight of ca. 357 is less than 500 it would still be
expected to be less absorption than the 100% default.
Once absorbed there is no specific
information on the metabolism, distribution and excretion of primary
fatty amine ethoxylates. However there is information
on the related primary fatty amines, metabolism distribution and
excretion of the primary fatty amine ethoxylates are expected to be
Primary alkylamines are not bioaccumulating
and metabolized rapidly by general oxidative pathways. They are
oxidatively deaminated by monoaminooxidases with concomitant formation
of ammonia and the corresponding alkylamine aldehyde. Subsequently, the
aldehydes are oxidised by aldehyde dehydrogenases to the corresponding
carboxylic acids, which, in turn, are further metabolized byβ-oxidation.
Carbon dioxide as the final product fromβ-oxidation is
exhaled. Urinary excretion is a minor elimination pathway.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again